Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement [Seeking Alpha]
Immunovant, Inc. (IMVT)
Company Research
Source: Seeking Alpha
I downgrade IMVT from "Strong Buy" to "Buy" due to competitive TED landscape and de-emphasis on batoclimab, despite robust upcoming catalysts. IMVT-1402 aims to address unmet needs in relapsed or uncontrolled GD patients, with pivotal data readouts expected in 2027 for additional indications like Myasthenia Gravis and difficult-to-treat rheumatoid arthritis. Recent $550M capital raise secures funding through potential IMVT-1402 commercial launch, supporting late-stage clinical programs and operational runway. gentlelight/iStock via Getty Images The last time I spoke about Immunovant IMVT ) it was with respect to a Seeking Alpha article entitled " Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward ". With respect More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm current
Show less
Read more
Impact Snapshot
Event Time:
IMVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMVT alerts
High impacting Immunovant, Inc. news events
Weekly update
A roundup of the hottest topics
IMVT
News
- Roivant Sciences Ltd. (ROIV) Analyst/Investor Day Transcript [Seeking Alpha]Seeking Alpha
- Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day [Yahoo! Finance]Yahoo! Finance
- Immunovant Announces Pricing of $550 Million Common Stock FinancingGlobeNewswire
- Immunovant (IMVT) Down 0.6% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]Yahoo! Finance
- Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings [Yahoo! Finance]Yahoo! Finance
IMVT
Earnings
- 11/10/25 - Miss
IMVT
Analyst Actions
- 9/30/25 - JP Morgan
IMVT
Sec Filings
- 12/12/25 - Form SCHEDULE
- 12/12/25 - Form 4
- 12/12/25 - Form 8-K
- IMVT's page on the SEC website